Back to today’s briefing

Story perspectives

San Francisco Firm Launches Weight Loss Trial for Cats

12/6/2025

35 5 Full Breakdown

Summary

Story summary

Okava Pharmaceuticals, based in San Francisco, will launch MEOW-1, a cat trial of glucagon-like peptide-1 (GLP-1) weight loss using the OKV-119 implant with 50 cats.
The effort aims to improve insulin sensitivity and reduce obesity-related health risks in cats.
About 60% of U.S. cats are overweight, raising diabetes risk.
If successful, FDA approval is targeted for 2027–2028, with roughly $100 monthly cost.
A similar dog treatment is in development.

1 of 1

Story summary

Okava Pharmaceuticals, based in San Francisco, will launch MEOW-1, a cat trial of glucagon-like peptide-1 (GLP-1) weight loss using the OKV-119 implant with 50 cats.
The effort aims to improve insulin sensitivity and reduce obesity-related health risks in cats.
About 60% of U.S. cats are overweight, raising diabetes risk.
If successful, FDA approval is targeted for 2027–2028, with roughly $100 monthly cost.
A similar dog treatment is in development.